At its inception the company was part of a joint venture with a Clinical Research Organisation (CRO) in the area of pharmaceutical R&D. Partnerships with Pharma and Biotech companies was derived as a natural consequence. This evolves into the formation of strategic partnerships. As an additional step MAB has generated a pipeline of R&D projects which will further change the company goals and structure.
MAB Discovery’s competitive position is unique. Despite the availability of many different alternative technologies the MAB work-flow has specific features that are not covered by other approaches. The main differentiation is the quality and quantity of outcome. The combination of immunisation and B-cell cloning strategies offers to generate hundreds to thousands of truly monoclonal antibody hits, all of the same IgG isotype. An automated work-flow will provide an accordingly high number of diverse, active recombinant humanised leads. Those can be differentiated by further in vitro and in vivo models. Partnered and internal R&D projects demonstrate successfully the value of the discovery work-flow.